EAST RUTHERFORD, N.J., May 9 /PRNewswire-FirstCall/ -- Cambrex Corporation
(NYSE: CBM), a leading provider to the healthcare industry, is pleased to
announce the appointment of David DeMarco Ph.D. as Vice President Strategic
Planning. Mr. DeMarco will direct the development and implementation of the
Company's transformational business strategy as Cambrex moves into the
specialty therapeutics market.
(Logo: http://www.newscom.com/cgi-bin/prnh/20000613/CAMBREXLOGO )
"We are very pleased to have Dave join Cambrex," commented John R. Leone,
Cambrex President and Chief Executive Officer. "His unique commercial skills,
creativity exploring strategic alternatives and experience in the
pharmaceutical industry will be beneficial as we advance Cambrex through its
natural progression from life sciences to specialty therapeutics." Mr. Leone
continued, "The appointment underscores our commitment to the healthcare
industry and our mandate to cultivate higher growth and more profitable
businesses."
Prior to joining Cambrex, Mr. DeMarco was Global Aesthetic Franchise
Leader for Sanofi-Aventis Dermatology where he implemented market strategies
that supported the global product line launches. He also served as Commercial
Head for Europe.
About Cambrex
Cambrex is a global, diversified life sciences company dedicated to
providing products and services to accelerate and improve the discovery and
commercialization of human therapeutics. The Company employs approximately
1900 worldwide. For more information, please visit http://www.cambrex.com.
Since the mid-1990's, Cambrex has helped customers develop their active
pharmaceutical ingredients (APIs) more efficiently and cost-effectively. The
Company has diagnosed and overcome problems that clients had in their
manufacturing processes, provided clinical or commercial quantities of
hundreds of pharmaceutical products and provided the analytical, regulatory
and other support services that clients need to shorten the time to market.
More recently, the Company expanded into the product commercialization arena
with sales and marketing services. The combined strength of experience,
breadth of products and services and success integrating over twenty
acquisitions supports the Company's strategy to move into the specialty
therapeutics market.
SOURCE Cambrex Corporation
 back to top
Related links:
http://www.cambrex.com
Photo Notes:http://www.newscom.com/cgi-bin/prnh/20000613/CAMBREXLOGO
Company News On-Call:
http://www.prnewswire.com/comp/134219.html
CONTACT:
Anne-Marie Hess, Director, Investor Relations
& Corporate Communications, 201-804-3062, or
annemarie.hess@cambrex.com
|
